1. Executive summary |
2. Global Uveitis Treatment Market Introduction |
2.1. Global Uveitis Treatment Market – Taxonomy |
2.2. Global Uveitis Treatment Market –Definitions |
2.2.1. Drug Class Type |
2.2.2. Disease Type |
2.2.3. Cause |
2.2.4. Distribution Channel |
3. Global Uveitis Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Uveitis Treatment Market Dynamics – Factors Impact Analysis |
3.6. Global Uveitis Treatment Market – Regulations |
3.6.1. U.S |
3.6.2. Europe |
3.6.3. Japan |
3.6.4. China |
3.7. Global Uveitis Treatment Market – Product Innovations |
4. Global Uveitis Treatment Market Analysis, 2017 – 2021and Forecast, 2022 – 2028 |
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Oppurtunity Analysis |
5. Global Uveitis Treatment Market, By Drug Class, 2017 – 2021and Forecast, 2017 – 2023 |
5.1. Corticosteroids |
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
5.1.3. Market Opportunity Analysis |
5.2. Immunosuppressant |
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
5.2.3. Market Opportunity Analysis |
5.3. Monoclonal antibodies |
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
5.3.3. Market Opportunity Analysis |
5.4. Antibiotics |
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
5.4.3. Market Opportunity Analysis |
5.5. Antivirals |
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
5.5.3. Market Opportunity Analysis |
5.6. Antifungal |
5.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
5.6.3. Market Opportunity Analysis |
5.7. Analgesics |
5.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
5.7.3. Market Opportunity Analysis |
6. Global Uveitis Treatment Market Forecast, By Disease Type, 2017 – 2021and Forecast, 2017 – 2023 |
6.1. Anterior Uveitis |
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
6.1.3. Market Opportunity Analysis |
6.2. Posterior Uveitis |
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
6.2.3. Market Opportunity Analysis |
6.3. Intermediate Uveitis |
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
6.3.3. Market Opportunity Analysis |
6.4. Panuveitis |
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
6.4.3. Market Opportunity Analysis |
7. Global Uveitis Treatment Market Forecast, By Cause, 2017 – 2021and Forecast, 2017 – 2023 |
7.1. Infectious Uveitis |
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
7.1.3. Market Opportunity Analysis |
7.2. Non-Infectious Uveitis |
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
7.2.3. Market Opportunity Analysis |
8. Global Uveitis Treatment Market Forecast, By Distribution Channel, 2017 – 2021and Forecast, 2017 – 2023 |
8.1. Hospital Pharmacies |
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
8.1.3. Market Opportunity Analysis |
8.2. Retail Pharmacies |
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
8.2.3. Market Opportunity Analysis |
8.3. Others |
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
8.3.3. Market Opportunity Analysis |
9. Global Uveitis Treatment Market Forecast, By Region, 2017 – 2021and Forecast, 2017 – 2023 |
9.1. North America |
9.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
9.2.3. Market Opportunity Analysis |
9.3. Asia-Pacific |
9.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
9.3.3. Market Opportunity Analysis |
9.4. Latin America |
9.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
9.4.3. Market Opportunity Analysis |
9.5. Middle East and Africa |
9.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis |
9.5.3. Market Opportunity Analysis |
9.6. Global Uveitis Treatment Market – Opportunity Analysis Index, By Drug Class Type, By Disease Type, Cause, Distribution Channel, and Region, 2022 – 2028 |
10. North America Uveitis Treatment Market Analysis, 2017 – 2021and Forecast, 2017 – 2023 |
10.1.1. Drug Class Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.1.1.1. Corticosteroids |
10.1.1.2. Immunosuppressant |
10.1.1.3. Monoclonal antibodies |
10.1.1.4. Antibiotics |
10.1.1.5. Antivirals |
10.1.1.6. Antifungal |
10.1.1.7. Analgesics |
10.1.2. Disease Type Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.1.2.1. Anterior Uveitis |
10.1.2.2. Posterior Uveitis |
10.1.2.3. Intermediate Uveitis |
10.1.2.4. Panuveitis |
10.1.3. Cause Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.1.3.1. Infectious Uveitis |
10.1.3.2. Non Infectious Uveitis |
10.1.4. Distribution Channel Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.1.4.1. Hospital Pharmacies |
10.1.4.2. Retail Pharmacies |
10.1.4.3. Others |
10.1.5. Country Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
10.1.5.1. U.S. |
10.1.5.2. Canada |
10.1.6. North America Uveitis Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2022 – 2028 |
10.1.7. North America Uveitis Treatment Market Dynamics – Trends |
11. Europe Uveitis Treatment Market Analysis, 2017 – 2021and Forecast, 2017 – 2023 |
11.1.1. Drug Class Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.1.1.1. Corticosteroids |
11.1.1.2. Immunosuppressant |
11.1.1.3. Monoclonal antibodies |
11.1.1.4. Antibiotics |
11.1.1.5. Antivirals |
11.1.1.6. Antifungal |
11.1.1.7. Analgesics |
11.1.2. Disease Type Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.1.2.1. Anterior Uveitis |
11.1.2.2. Posterior Uveitis |
11.1.2.3. Intermediate Uveitis |
11.1.2.4. Panuveitis |
11.1.3. Cause Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.1.3.1. Infectious Uveitis |
11.1.3.2. Non Infectious Uveitis |
11.1.4. Distribution Channel Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.1.4.1. Hospital Pharmacies |
11.1.4.2. Retail Pharmacies |
11.1.4.3. Others |
11.1.5. Country Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.1.5.1. Germany |
11.1.5.2. UK |
11.1.5.3. France |
11.1.5.4. Spain |
11.1.5.5. Italy |
11.1.5.6. Russia |
11.1.5.7. Poland |
11.1.5.8. Rest of Europe |
11.1.6. Europe Uveitis Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2022 – 2028 |
11.1.7. Europe Uveitis Treatment Market Dynamics – Trends |
12. Asia-Pacific Uveitis Treatment Market Analysis, 2017 – 2021and Forecast, 2017 – 2023 |
12.1.1. Drug Class Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.1.1.1. Corticosteroids |
12.1.1.2. Immunosuppressant |
12.1.1.3. Monoclonal antibodies |
12.1.1.4. Antibiotics |
12.1.1.5. Antivirals |
12.1.1.6. Antifungal |
12.1.1.7. Analgesics |
12.1.2. Disease Type Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.1.2.1. Anterior Uveitis |
12.1.2.2. Posterior Uveitis |
12.1.2.3. Intermediate Uveitis |
12.1.2.4. Panuveitis |
12.1.3. Cause Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.1.3.1. Infectious Uveitis |
12.1.3.2. Non Infectious Uveitis |
12.1.4. Distribution Channel Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.1.4.1. Hospital Pharmacies |
12.1.4.2. Retail Pharmacies |
12.1.4.3. Others |
12.1.5. Country Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), |
Y-o-Y Growth (%), and Market Share (%) |
12.1.5.1. Japan |
12.1.5.2. China |
12.1.5.3. India |
12.1.5.4. ASEAN |
12.1.5.5. Australia & New Zealand |
12.1.5.6. Rest of Asia-Pacific |
12.1.6. Asia-Pacific Uveitis Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2022 – 2028 |
12.1.7. Europe Uveitis Treatment Market Dynamics – Trends |
13. Latin America Uveitis Treatment Market Analysis, 2017 – 2021and Forecast, 2017 – 2023 |
13.1.1. Drug Class Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.1.1.1. Corticosteroids |
13.1.1.2. Immunosuppressant |
13.1.1.3. Monoclonal antibodies |
13.1.1.4. Antibiotics |
13.1.1.5. Antivirals |
13.1.1.6. Antifungal |
13.1.1.7. Analgesics |
13.1.2. Disease Type Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.1.2.1. Anterior Uveitis |
13.1.2.2. Posterior Uveitis |
13.1.2.3. Intermediate Uveitis |
13.1.2.4. Panuveitis |
13.1.3. Cause Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.1.3.1. Infectious Uveitis |
13.1.3.2. Non Infectious Uveitis |
13.1.4. Distribution Channel Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.1.4.1. Hospital Pharmacies |
13.1.4.2. Retail Pharmacies |
13.1.4.3. Others |
13.1.5. Country Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.1.5.1. Brazil |
13.1.5.2. Mexico |
13.1.5.3. Argentina |
13.1.5.4. Venezuela |
13.1.5.5. Rest of Latin America |
13.1.6. Latin America Uveitis Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2022 – 2028 |
13.1.7. Latin America Uveitis Treatment Market Dynamics – Trends |
14. Middle East and Africa Uveitis Treatment Market Analysis, 2017 – 2021and Forecast, 2017 – 2023 |
14.1.1. Drug Class Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
14.1.1.1. Corticosteroids |
14.1.1.2. Immunosuppressant |
14.1.1.3. Monoclonal antibodies |
14.1.1.4. Antibiotics |
14.1.1.5. Antivirals |
14.1.1.6. Antifungal |
14.1.1.7. Analgesics |
14.1.2. Disease Type Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
14.1.2.1. Anterior Uveitis |
14.1.2.2. Posterior Uveitis |
14.1.2.3. Intermediate Uveitis |
14.1.2.4. Panuveitis |
14.1.3. Cause Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
14.1.3.1. Infectious Uveitis |
14.1.3.2. Non Infectious Uveitis |
14.1.4. Distribution Channel Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
14.1.4.1. Hospital Pharmacies |
14.1.4.2. Retail Pharmacies |
14.1.4.3. Others |
14.1.5. Country Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
14.1.5.1. Gulf Cooperation Council (GCC) Countries |
14.1.5.2. Israel |
14.1.5.3. South Africa |
14.1.5.4. Rest of MEA |
14.1.6. MEA Uveitis Treatment Market – Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2022 – 2028 |
14.1.7. MEA Uveitis Treatment Market Dynamics – Trends |
15. Competition Landscape |
15.1. Strategic Dashboard of Top Market Players |
15.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
15.2.1. AbbVie Inc. (U.S.) |
15.2.2. Eyegate Pharmaceuticals Inc. (U.S.) |
15.2.3. Valeant Pharmaceuticals (Bausch + Lomb) (Canada) |
15.2.4. Novartis AG (Switzerland) |
15.2.5. Alimera Sciences Inc. (U.S.) |
15.2.6. Santen Pharmaceutical Co. Ltd (Japan) |
16. Research Methodology |
17. Key Assumptions and Acronyms |